Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A., Licitra, L. F., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F. P., Haddad, R. I., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., Gillison, M. L. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.6009

View details for Web of Science ID 000404711502137